# N-Acetyl Cystein and Contrast Nephropathy

Study · id `cardio:ct-nct01820195` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01820195](<https://clinicaltrials.gov/study/NCT01820195>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01820195

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 549 participants.

## Technical summary

Registry record NCT01820195. Randomized; double masking; primary purpose prevention. Start 2013-03 (registry gives no type); primary completion 2014-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 549 participants (planned count; ClinicalTrials.gov record NCT01820195, source copy `cardio:ctgov-nct01820195-2013-03-28`, retrieved 2026-10-26)
- Start date: 2013-03 (registry gives no type) (ClinicalTrials.gov record NCT01820195, source copy `cardio:ctgov-nct01820195-2013-03-28`, retrieved 2026-10-26)
- Primary completion: 2014-08 (anticipated) (ClinicalTrials.gov record NCT01820195, source copy `cardio:ctgov-nct01820195-2013-03-28`, retrieved 2026-10-26)
- Completion: 2014-11 (anticipated) (ClinicalTrials.gov record NCT01820195, source copy `cardio:ctgov-nct01820195-2013-03-28`, retrieved 2026-10-26)
- Countries: Iran (ClinicalTrials.gov record NCT01820195, source copy `cardio:ctgov-nct01820195-2013-03-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01820195-2013-03-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: N-Acetyl Cystein and Contrast Nephropathy
- Condition: Chronic Kidney Disease Stage 2
- Condition: Radiographic Contrast Agent Nephropathy
- Intervention (Drug): Oral N-Acetyl Cystein
- Intervention (Drug): IV N-Acetyl Cystein
- Intervention (Drug): Placebo group
- Lead sponsor: Imam Khomeini Hospital
- Lead sponsor class: OTHER
- Collaborator: Tehran Heart Center
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 6aed5c4d2118c25461a88ebf90e096f74ed8351b4be05857af5710e8e20613cd
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
